Original Article

Early Reduction of SARS-CoV-2 Replication in Bronchial Epithelium by Kinin B_2 Receptor Antagonism

Short title: B_2R Antagonist Suppresses SARS-CoV-2 Replication

Constanze A. Jakwerth[1*], Martin Feuerherd[2*], Ferdinand M. Guerth[1], Madlen Oelsner[1], Linda Schellhammer[3], Johanna Giglberger[1,6], Lisa Pechtold[6], Claudia Jerin[1,6], Luisa Kugler[6], Carolin Mogler[4], Bernhard Haller[5], Anna Erb[1], Barbara Wollenberg[6], Christoph D. Spinner[7], Thorsten Buch[3], Ulrike Protzer[2], Carsten B. Schmidt-Weber[1,§], Ulrich M. Zissler[1#], Adam M. Chaker[1,6#]

1) Center of Allergy & Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, German Research Center for Environmental Health, Member of the German Center for Lung Research (DZL), CPC-M, Munich, Germany
2) Institute of Virology, Technical University of Munich/Helmholtz Zentrum München, Munich, Germany; German Center of Infectiology Research (DZIF), Munich partner site, Munich, Germany
3) Institute of Laboratory Animal Science, University of Zurich, Zurich, Switzerland
4) Institute of Pathology, Technical University Munich, Munich, Germany
5) Institute of Medical Informatics, Statistics and Epidemiology, Medical School, Technical University of Munich
6) Department of Otorhinolaryngology and Head and Neck Surgery, Medical School, Technical University of Munich, Germany
7) Department of Internal Medicine II, University Hospital rechts der Isar, Medical School, Technical University of Munich, Munich, Germany
*) These authors contributed equally
#) These senior authors contributed equally

§) Corresponding author:
Prof. Dr. Carsten B. Schmidt-Weber, Chair & Director
Center of Allergy & Environment (ZAUM)
Technical University and Helmholtz Center Munich
Biedersteiner Str. 29
80202 Munich, Germany
Email: csweber@tum.de
Phone: +49 89 4140 345

Conflict of interests:

Dr. Jakwerth reports grants from Federal Ministry of Education and Research, grants from European Institute of Innovation & Technology (EIT), during the conduct of the study. Mr. Feuerherd reports personal fees from Helmholtz Zentrum München and Dr. Höhnle AG, outside the submitted work. Dr. Spinner reports grants, personal fees, non-financial support and other from AbbVie, grants, personal fees, non-financial support and other from Apeiron, personal fees from Formycon, grants, personal fees, non-financial support and other from Gilead Sciences, grants, personal fees and other from Eli Lilly, grants, personal fees, non-financial support and other from Janssen-Cilag, grants, personal fees, non-financial support and other from GSK/ViiV Healthcare, grants, personal fees, non-financial support and other from MSD, outside the submitted work. Prof. Dr. Buch reports personal fees from Virometix AG, other from Virometix AG, other from Trials24 GmbH, other from Clemedi AG, outside the submitted work. Prof. Dr. Protzer reports grants from the Federal Ministry of Education and Research, the German Center for Infection Research (DZIF), the German Research Foundation (DFG), the European Union via Horizon 2020 and the Bavarian Research Foundation during conduct of the study. She receives personal fees as an ad hoc scientific advisor from Abbvie, Arbutus, Gilead, GSK, Johnson & Johnson, Vaccitech. Prof. Dr. Schmidt-Weber reports grants from German Center for Lung Research (DZL), grants from Comprehensive Pulmonary Lung Center (CPC) Munich during the conduct of the study. Personal Fees from Allergopharma and Bencard, outside the submitted work. Dr. Zissler reports grants from Federal Ministry of Education and Research, during the conduct of the study. Dr. Chaker reports grants for clinical studies and research and other from Allergopharma, ALK Abello, AstraZeneca, Bencard / Allergen Therapeutics, ASIT Biotech, Lofarma, GSK, Novartis, LETI, Inmunotek, Roche, Sanofi Genzyme, Zeller and from the European Institute of Technology (EIT); has received travel support from the European Academy of Allergy and Clinical Immunology (EAACI), DGAKI, all outside the submitted work. In addition, Drs. Jakwerth, Feuerherd, Protzer,

Schmidt-Weber, Zissler and Chaker are named as inventors on the patent application 'Novel approaches for treatment of SARS-CoV2-Infection in a patient'. Mr. Guerth, Ms. Oelsner, Dr. Schellhammer, Ms. Giglberger, Ms. Pechtold, Dr. Jerin, Ms. Kugler, Dr. Mogler, Dr. Haller, Ms. Erb, Prof. Dr. Wollenberg have nothing to disclose.

Funding: This study was supported by funding from the German Center of Lung Research (DZL), the Comprehensive Pneumology Center (CPC) Munich, the German Research Foundation (DFG; 398577603, TR22), and the Federal Ministry of Education and Research (ESCAPE; 01KI20169A).

Author contributions:

Study design A.M.C., C.S.W., U.P., C.A.J., M.F., U.M.Z., T.B.; collection of patient samples A.M.C., J.G., L.P., Cl.J., L.K.; conduction of experiment C.A.J., M.F., F.G., M.O., C.M., L.S., J.G., L.K.; data collection C.A.J., M.F., F.G., M.O., U.M.Z., C.M., L.S., J.G., L.P., Cl.J., L.K.; data analysis C.A.J., M.F., F.G., A.E., U.M.Z., C.M., B.H., L.S.; data interpretation A.M.C., C.S.W., U.P., C.A.J., M.F., U.M.Z., C.M., B.H., C.D.S., B.W., L.S., T.B.; literature search A.M.C., C.S.W., C.A.J., M.F., U.M.Z., A.E.; writing all authors.

ABSTRACT (247/250 words)

Background: SARS-CoV2 has evolved to enter the host via the ACE2 receptor which is part of the Kinin-kallirein pathway. This complex pathway is only poorly understood in context of immune regulation but critical to control infection. This study examines SARS-CoV2 infection and epithelial mechanisms of the kinin-kallikrein system at the kinin B_2 receptor level in SARS-CoV-2 infection that is of direct translational relevance.

Methods: From acute SARS-CoV-2-positive patients and -negative controls, transcriptomes of nasal brushings were analyzed. Primary airway epithelial cells (NHBEs) were infected with SARS-CoV-2 and treated with the approved B_2R antagonist icatibant. SARS-CoV-2 RNA RT-qPCR, cytotoxicity assays, plaque assays and transcriptome analyses were performed. The treatment effect was further studied in a murine airway inflammation model *in vivo*.

Results: Here, we report a broad and strong upregulation of kallikreins and the kinin B_2 receptor (B_2R) in the nasal mucosa of acutely symptomatic SARS-CoV-2-positive patients. A B_2R antagonist impeded SARS-CoV-2 replication and spread in NHBEs, as determined in plaque assays on Vero E6 cells. B_2R antagonism reduced the expression of SARS-CoV-2 entry receptor ACE2 *in vitro* and in a murine airway inflammation model *in vivo*. In addition, it suppressed gene expression broadly, particularly genes involved in G-protein-coupled-receptor signaling and ion transport.

Conclusions: In summary, this study provides evidence that treatment with B_2R antagonists protects airway epithelial cells from SARS-CoV-2 by inhibiting its replication and spread, through the reduction of ACE2 levels and the interference with several cellular signaling processes. Future clinical studies need to shed light on the airway protection potential of approved B_2R antagonists, like icatibant, in the treatment of early-stage COVID-19.

Key words: ACE2; COVID-19; kinin B_2R antagonist; kinin-kallikrein system; SARS-CoV-2

Abbreviations:

ACE2	angiotensin-converting enzyme 2
ant-B_2R	kinin B_2 receptor antagonist
BDKRB1	kinin B_1 receptor (gene name)
BDKRB2	kinin B_2 receptor (gene name)
B_1R	kinin B_1 receptor
B_2R	kinin B_2 receptor
B_2R antagonist	kinin B_2 receptor antagonist
CAS	contact activation system
COVID-19	coronavirus disease of 2019
DABK	des-Arg9-bradykinin
GPCR	G protein-coupled receptor
HC	hydrocortisone
HMW-kininogen	high-molecular-weight-kininogen
IC50	half maximal inhibitory concentration
KKS	kinin-kallikrein system
LDH	lactate dehydrogenase
NHBE	normal human bronchial epithelial cells
RAS	renin-angiotensin system
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus-2
TMPRSS	transmembrane serine protease

Word count: 3,476 / 3,500

1 INTRODUCTION

SARS-CoV-2 vaccines have been approved worldwide since the end of 2020 and are starting to show their protective effects in public health.[1,2] Even with vaccines at hand, an important medical need for therapeutic approaches for COVID-19 remains: Parts of the population refrain from vaccination or are not eligible for it, immunocompromised individuals may not mount a sufficient immune response after vaccination and escape variants, such as the currently spreading SARS-CoV-2 variant Delta[3], may breach the protection afforded by the vaccines.[4-9] Key factors for SARS-CoV-2 cell entry are two cell surface molecules, the angiotensin-converting enzyme 2 (ACE2) and the transmembrane serine protease (TMPRSS)2.[10] TMPRSS2 cleaves the coronaviral spike protein and primes it for cell fusion, while ACE2 enables the virus particle to enter the cell by binding of its spike protein.[11,12] The latter acts as central component in its function as terminal carboxypeptidase in the counter-regulatory axis of the renin-angiotensin system (RAS) and the contact activation system (CAS),[10,13] which initiates blood coagulation and can additionally activate the kinin-kallikrein system (KKS).[14] In its role in the RAS, ACE2 has anti-vasoconstrictive and anti-inflammatory effects by hydrolyzing the vasoconstrictive and tissue-damaging angiotensin II, which contributes to airway remodeling and fibrosis,[15,16] to angiotensin (1-7).[17] In its role in the KKS, ACE2 further hydrolyzes vasoactive peptides such as des-Arg9-bradykinin (DABK), which activates the inflammatory axis of the KKS.[18,19] While DABK is the ligand of the inducible kinin B_1 receptor (*BDKRB1*; B_1 receptor),[20] bradykinin, the end product of the KKS cascade, binds to the constitutively expressed kinin B_2 receptor (*BDKRB2;* B_2 receptor; B_2R) and activates it.[21] Bradykinin mediates its pro-inflammatory effects via the B_2 receptor, by eliciting a variety of responses, including vasodilation and edema, via the G protein-triggered phosphatidylinositol-calcium second messenger system.[22-26]

156 The fact that SARS-CoV-2 utilizes ACE2 to enter airway cells along with the fact that ACE2
157 is a multifunctional enzyme that counter-regulates the ACE-driven mechanisms of the RAS and
158 balances the KKS, may therefore explain the serious course of COVID-19, not only in the lungs
159 but systemically.[27,28]
160 Recent publications suggest that the KKS could play a role in COVID-19. KKS comes into play
161 particularly in connection with the high prevalence of thromboembolic events in seriously ill
162 COVID-19 patients.[7,18,20,29,30] A recent study on a cohort of 66 COVID-19 patients admitted to
163 the intensive care unit showed that the KKS was strongly activated, which was reflected in the
164 consumption of factor XII, pre-kallikrein and high-molecular-weight kininogen (HMW-
165 kininogen).[29] It has further been hypothesized that kinin-dependent "local lung angioedema"
166 involving the kinin B_1 and B_2 receptors is an important characteristic of COVID-19.[31-34]
167 This study examines the potential of interfering with the KKS at the kinin receptor level in
168 SARS-CoV-2 infection with translational relevance. Based on a broad and strong upregulation
169 of kallikreins and of the kinin B_2 receptor in the nasal mucosa of acutely SARS-CoV-2-positive
170 patients, we hypothesized that the B_2 receptor antagonism using icatibant, an approved
171 compound for the treatment of hereditary angioedema,[35] had an early protective effect against
172 SARS-CoV-2-mediated epithelial damage through disruption of ACE2-mediated virus entry.
173

2 MATERIALS AND METHODS

2.1 Patients and nasal brushings

The nasal brushings were performed as a part of a larger health professional observational cohort study, which was approved by the ethics commission of the Technical University of Munich (AZ 175/20s). Nasal brushings were subjected to whole-genome microarray transcriptome analysis (see Supp.Info.). All patients gave written, informed consent prior to participation (see Table 1).

2.2 *In vivo* mouse study

Mice received murine IL-12Fc (1 µg of protein in 50 µL PBS) or PBS control intranasally.[36] Intranasal application was performed under isoflurane anesthesia in two steps of 25 µL per nostril. 48 hours later, the mice received a single subcutaneous injection of icatibant (2 nmol per 10 g body weight; HOE-140 (icatibant), H157, SLBX4410, Sigma) or PBS control. The experiment was terminated by CO_2 asphyxiation 6 hours or 24 hours after the injection of icatibant. The experiment was carried out twice Organs were snap frozen for protein extraction. Mice enrolled in the experiment were 6-8 weeks old, from either C57BL/6J, BALB/c or C3H HeN strains. Both sexes were included for each strain and means of each mouse type (strain / sex) are depicted as single values in Fig.2A: circle: female; triangle: male. Black: C57BL/6, mid grey: C3H HeN, light grey: BALB/c strain. Experiments were performed and analyzed in a randomized and blinded fashion. Animals were obtained from Janvier Labs (Le Genest-Saint-Isle, France) and housed 5 per cage and sex in individually ventilated cages at Laboratory Animal Service Center of the University of Zurich in Schlieren (Schlieren, Zurich, Switzerland). The animal vivarium was a specific-pathogen-free (SPF) holding room, that was temperature- and humidity-controlled (21 ± 3 °C, 50 ± 10%), with a 12h light/dark cycle. All animals had ad libitum access to the same food and water throughout the entire study. All procedures described in this study had previously been approved by the Cantonal Veterinarian's

Office of Zurich, Switzerland (License ZH096/20), and every effort was made to minimize the number of animals used and their suffering. Experiments were pre-registered at www.animalstudyregistry.org (study title "Effect of drug on ACE2 levels in mice"; doi=10.17590/asr.0000225).

Detailed methods are provided in the online supporting information.

3 RESULTS

3.1 B_2 receptor antagonist inhibits replication and spread of SARS-CoV-2

The enzyme ACE2 is the central viral entry receptor for the novel SARS-CoV-2 coronavirus on human epithelial cells of the respiratory tract.[10] Recent studies showed that this receptor and its co-receptors are not only expressed in the lower respiratory tract, and thus on the alveolar epithelial cells type I and II, but are also present in the upper respiratory tract, but are predominantly expressed in the nasal mucosa.[37]

To investigate the local effect of the acute SARS-CoV-2 infection on the nasal epithelium, we analyzed the transcriptome of nasal brushings from symptomatic patients who tested acutely positive for SARS-CoV-2 and of SARS-CoV-2-negative patients. In a transcriptome analysis, the most strongly induced genes encoding secreted factors included many members of the kallikrein family (Fig.1A, Table S1). In particular, the kallikreins *KLK5*, *KLK9* and *KLK12* were significantly upregulated in acute SARS-CoV-2-positive patients compared to SARS-CoV-2-negative patients (Fig.1B, Table S2). A subsequent analysis focusing on central factors of the KKS revealed that in addition, the kinin receptor B_2 (*BDKRB2*; B_2R) was also significantly increased (Fig.1C, Table S3). This first finding, together with our hypothesis that ACE2, as a central component, is counter-regulated by intervention in the KKS, prompted us to investigate selective kinin B_2 receptor antagonism in connection with SARS-CoV-2 infection. To circumvent the limitations of cell lines like Vero E6, A549 or Calu-3 cells that are intrinsically impaired to form an interferon response upon viral infection,[38] we next infected primary bronchial epithelial (NHBE) cells with SARS-CoV-2.

To examine the effects of SARS-CoV-2 infection and B_2R antagonist treatment on the microscopic integrity of the airway epithelium, 3D-air-liquid interphase organoid cultures were differentiated from primary NHBEs (see Supp.Info). After complete differentiation, the epithelia were pre-treated from the basal (medium) side with the approved B_2R antagonist icatibant, and subsequently infected with SARS-CoV-2 from the apical (air) side. The cultures

pre-treated with the B_2R antagonist showed less virus-induced balloon-like structures compared to untreated cultures. The epithelial layers remained qualitatively more intact, which indicated a protective effect of the B_2R antagonist for the bronchial epithelium (Fig.1D). This finding was further strengthened by cytotoxicity assays: The B_2R antagonist had no toxic effects on NHBEs even at high doses determined by lactate dehydrogenase (LDH) release, but rather exhibited a cell-protecting effect in uninfected cells (Fig.1E) as well as during SARS-CoV-2 infection (Fig.1F). Next, the supernatants of pre-treated, infected primary NHBEs were collected, titrated onto fresh Vero E6 cell cultures and plaque assays were performed. Strikingly, we found that *in vitro* treatment of NHBEs with the B_2R antagonist prior to infection reduced the number of plaque forming units (PFU) in a plaque assay by 87% (Fig.1G). In addition, the levels of total SARS-CoV-2 RNA in cells that had been pretreated with the B_2R antagonist decreased by 52% compared to untreated infected NHBEs (Fig.1H). With regard to the virus entry process, ACE2 was reduced by pretreatment with the B_2R antagonist on the mRNA level (Fig. 1I) and on the protein level (Fig. 1J). The membrane-standing protease TMPRSS2 cleaves the spike protein for SARS-CoV-2 and primes it therefore for optimized binding to its entry receptor ACE2. In contrast to ACE2, the *TMPRSS2* transcript levels were significantly increased in infected compared to uninfected NHBEs but were not affected by B_2R antagonist pre-treatment (Fig.S2A). Further experiments on the effect of the B_2R antagonist on the SARS-CoV-2 infection of NHBE showed that pre-treatment with the B_2R antagonist significantly reduced infection-mediated cytotoxicity measured by LDH release (Fig.1F).

3.2 Repetitive treatment with B_2R antagonist inhibits SARS-CoV-2 replication and spread post-infection

The finding that B_2R antagonism leads to a downregulation of ACE2 protein levels in lung epithelial cells was confirmed *in vivo* in a murine airway inflammation model. 24 sex-matched

mice from three different strains per group were treated in two blocks intranasally with murine IL-12Fc to mimic virus-induced airway inflammation via activation of the IL-12 / IFN-γ axis.[36] After 48 hours, mice were injected subcutaneously (s.c.) with the B_2R antagonist and the experiment was terminated six hours or 24 hours later. IL-12Fc-pretreated mice, which were then further treated with the B_2R antagonist on day 2, had significantly reduced ACE2 protein levels in the lungs after six hours compared to control mice, which were only treated with PBS on day 2 (Fig.2A). This effect decreased after 24 hours.

Anticipating treatment of SARS-CoV-2 infected patients with the B_2R antagonist icatibant, NHBEs were first infected with SARS-CoV-2 and then treated with the B_2R antagonist six hours after infection. Confirming the results of the pre-treatment, post-infection treatment with the B_2R antagonist also attenuated the cytopathic effect of SARS-CoV-2 (Fig.2B) and reduced the number of PFU in a plaque assay on Vero E6 cells by 84% (Fig.2C).

We also aimed to reflect pharmacokinetics[39] during treatment of early infection by treating NHBEs post-infection every 24 hours with the B_2R antagonist repeatedly for a period of 96 hours, reflecting the drug administration of this particular substance in real life. In cells treated post-infection with 100 nM icatibant for 48 hours, the total viral RNA (Fig.2D-F IC_{50}(total RNA 48h)=92.93; IC_{50}(total RNA 72h)=91.56) and also the genomic viral RNA (Fig.2G-I; IC_{50}(total RNA 48h)=17.01; IC_{50}(total RNA 72h)=7.412) were significantly reduced by 49% and 42% on average, respectively. Treatment with 1000 nM icatibant for 48 hours led to a reduction of the total SARS-CoV-2 RNA (Fig.2D-F) and also of the genomic SARS-CoV-2 RNA (Fig.2G-I) by 69% and 56% on average, respectively. The genomic viral RNA was detected using RT-qPCR against the sequence of the SARS-CoV-2 RNA-dependent RNA polymerase (*RdRP*), which is only found in virions as well as during the viral replication. On the other hand, total viral RNA was detected with qPCR targeting a sequence of the SARS-CoV-2 *N* gene that is present in the viral genome and also in every SARS-CoV-2 protein-encoding transcript. The reduction in total SARS-CoV-2 RNA and genomic viral RNA during

284 treatment with the B_2R antagonist was comparable at the indicated concentrations and time
285 points (Fig.2D-I).
286
287 **3.3 B_2 receptor antagonism broadly silences gene expression in bronchial epithelial cells**
288 **while maintaining cell-intrinsic antiviral response**
289 Severe cases of COVID-19 develop cytokine storms[40-42] characterized by excessive systemic
290 release of multiple cytokines including IP-10 (*CXCL10*), IL-6, IL-8 (*CXCL8*), and IL-10.[43-46]
291 These cases are currently treated with immunomodulating drugs, such as corticosteroids or
292 biologics, like tocilizumab[47], though these treatments may interfere with or alter the antiviral
293 immune response. We therefore compared the effect of the B_2R antagonist on gene expression
294 of the bronchial epithelium in the light of SARS-CoV-2 infection with the effect of
295 hydrocortisone. While the B_2R antagonist mainly suppressed epithelial gene expression during
296 infection, the effects of hydrocortisone on gene induction and gene repression were equal
297 (Fig.3A, Tables S4-5). This finding matches previous reports.[48] Therefore, conditions were
298 compared in respect to the antiviral epithelial response. In fact, differentially expressed genes
299 (DEGs) induced by SARS-CoV-2 infection in NHBEs encompassed type-I and -III interferons
300 as well as IFN-inducible and antiviral *APOBEC* genes (Fig.S1E, Table S6). In particular,
301 SARS-CoV-2 infection induced the antiviral cytidine deaminases APOBEC3A and B, which
302 we previously described to be induced by type-I interferons in the treatment of hepatitis-B virus
303 infection.[49] On the other hand, *APOBEC3C* mRNA levels were decreased in SARS-CoV-2-
304 infected NHBE, which could indicate a novel evasion mechanism.[50] Neither the B_2R antagonist
305 nor hydrocortisone inhibited the expression of genes with cell-intrinsic antiviral effects and
306 even increased the antiviral factor *APOBEC3A* at the mRNA level (Fig.3B, Table S7).[51]
307 Our gene expression analysis data show that SARS-CoV-2 infection also induces the expression
308 of acute-phase proteins, such as TNF-α and IL-8 (*CXCL8*),[52,53] as well as IL-17C, MIP-
309 3α (*CCL20*), IL-36γ[54,55] and the chemokines CXCL1, -2, -3, -8, -17, CCL2, -3, -5[54] in primary

lung epithelial cells (Fig.3C, Table S8). The induction of these factors most likely contributes to the recruitment and activation of relevant immune cells to the site of infection. Our findings are supported by previous studies of aberrant macrophage and T cell responses underlying immunopathogenesis in bronchoalveolar lavage fluid from COVID-19 patients.[56] In addition, the gene expression of acute-phase proteins was not significantly affected in airway epithelial cells by the B_2R antagonist or hydrocortisone treatment (Fig.3C, Table S8). Neither drug interfered with canonical cellular antiviral – and reaction-triggering response mechanisms, showing great potential for treatment options of COVID-19 while maintaining the host's antiviral immune response.

In addition, we found that SARS-CoV-2 infection increases the expression of three known and postulated entry (co-)receptors: 1) the transmembrane serine protease TMPRSS11A (Fig.S1C, Tables S6,9-13), which was described to prime the MERS coronavirus spike protein[57], 2) the transmembrane serine protease TMPRSS11D, which was shown to activate SARS-CoV-2 spike protein[58] and 3) the pathogen-associated molecular pattern-binding C-type lectin receptor DC-SIGN (*CD209*), which was described to serve as entry receptor for SARS-CoV[59] and has been suggested to act as a receptor also for SARS-CoV-2. The induction of these additional entry receptor candidates triggered by SARS-CoV-2 infection may potentiate the viral spread in the bronchial epithelium and thus represent a pathogenetic approach that needs further research.

Overall, treatment with the B_2R antagonist and hydrocortisone had no significant effects on the expression of these candidate viral entry receptors (Fig.3D, Table S14). On the other hand, hydrocortisone enhanced the expression of TMPRSS proteases (Fig.3D). In particular, when focusing on the known SARS-CoV-2 entry receptors, hydrocortisone treatment of uninfected cells was already sufficient to induce an increase in *TMPRSS2* gene expression (Fig.3E). SARS-CoV-2 infection per se also increased *TMPRSS2* expression, and pre-treatment of SARS-CoV-2-infected NHBEs with hydrocortisone further potentiated this effect. On the other hand, *ACE2* expression showed only a slight upward trend after hydrocortisone pretreatment (Fig.S2B).

Finally, the hydrocortisone pre-treatment of SARS-CoV-2-infected NHBEs had no inhibitory effect on the release of infectious particles 24 hours after infection (Fig.3F), which was expected since the treatment of COVID-19 patients with corticosteroids has an immunomodulatory rationale.

3.4 B_2 receptor antagonist counter-balances virus-induced gene expression, particularly genes involved in G protein-coupled receptor (GPCR) signaling and ion transport

With regard to the genes that are attenuated at the mRNA level by B_2R antagonism, the DEGs were analyzed in a network analysis using the database string to identify enriched cellular processes. B_2R antagonism reduced the expression levels of 343 membrane-bound receptors significantly in treated versus untreated SARS-CoV-2-infected NHBEs (Table S15). Two particular cellular processes affected by pre-treatment with the B_2R antagonist were identified, namely G protein-coupled receptor signaling (GO:0007186; Fig.4A, S2C, Tables S4,S17-18) and ion transport (GO:0006811; Fig.4B, Tables S4,17-18). DEGs involved in both processes were significantly downregulated in treated versus untreated SARS-CoV-2-infected NHBEs (Tables 16-18). Notably, all 35 cell surface receptors induced by SARS-CoV-2 infection were downregulated in cells that were treated with the B_2R antagonist (Fig.4C,D, Tables S19-20).

4 DISCUSSION

In this study, we provide evidence for the effect of interference with the KKS at the kinin B_2 receptor level as a means of protecting the airway epithelium from SARS-CoV-2 infection, while maintaining canonical cell-intrinsic antiviral response.

We initially hypothesized that through KKS interference, either feedback mechanisms or modulated signal transduction target the virus entry receptor ACE2 and thus interfere with the spread of SARS-CoV-2. To this end, the approved B_2R antagonist icatibant was used in this study. Here, we demonstrate that treatment with a B_2R antagonist inhibits the replication and spread of SARS-CoV-2 in primary airway epithelial cells, which was determined by a decrease in total and genomic SARS-CoV-2 RNA, resulting in less infectious particles in plaque assays, both when applied pre- and post-infection. While a low concentration of 1 nM B_2R antagonist was sufficient to reduce viral RNA in primary bronchial epithelial cells when cells were treated pre-infection, 100 nM B_2R antagonist was required to this effect, when cells were treated post-infection. In addition, the significant reduction in virus load as determined by PCR tapered off after 96 hours. On the one hand, *in vitro* infections are performed with excess amounts of virus particles. On the other hand, the fact that, due to its constitution as a peptide analog, the B_2R antagonist icatibant used in this study has a short half-life in the human body[39] but also pharmacological tolerance to interference at receptor level may explain why the effect reached significance after six hours but did not persist. Therefore, a higher dose of the B_2R antagonist may be required at even shorter repetitive dosing intervals to inhibit virus replication in the long term. Therapeutic application in future dose finding studies should therefore focus on early intervention with at least two doses daily[60] and on either optimized pharmacokinetics or increased high local tissue concentrations, e.g. through topical application.

Two potential mechanisms of action for suppressing SARS-CoV-2 replication and spread in airway epithelium are revealed by the current study:

1) Treatment with the B_2R antagonist led to a downregulation of the viral entry receptor ACE2, *in vitro* in primary airway epithelial cells and *in vivo* in a murine airway inflammation model. Since the decrease of genomic SARS-CoV-2 RNA and total SARS-CoV-2 RNA was comparable, we conclude that the B_2R antagonist icatibant does probably not affect the viral transcription machinery but inhibits the infection rather on the levels of entry, protein synthesis/processing and assembly, maturation or budding.

In comparison, the corticosteroid hydrocortisone even upregulated TMPRSS2 in infected airway epithelial cells. It is noteworthy that hydrocortisone did not change the release of infectious particles from infected airway epithelial cells into the supernatant. Although TMPRSS2 expression was even enhanced by hydrocortisone, our data implicate that this effect on TMPRSS2 alone is insufficient to increase susceptibility for SARS-CoV-2 infection.

2) Treatment with the B_2R antagonist had a broad suppressive effect on gene expression of multiple cell signaling molecules, in particular on membrane-standing factors involved in GPCR signaling and ion transport.

It has recently been published that SARS-CoV-2 may use cellular GPCR signaling pathways, thereby modulate epithelial transport mechanisms involved in ion transport and thereby cause a local ion imbalance in the airways.[61] In addition, an extensive recent study described that intracellular SARS-CoV-2 protein interactions include factors involved in intracellular trafficking and transport, particularly ion transport and solute carrier transport.[62] In fact, the SARS-CoV-2 infection led to a differential regulation of the gene expression of 12 potassium channel (5 upregulated / 7 downregulated), 1 sodium channel (down), but in particular of 55 members of the solute carrier family (24 downregulated / 31 upregulated) in primary airway epithelial cells. On the other hand, B_2R antagonist treatment of SARS-CoV-2-infected NHBE resulted in a downregulation of 20 potassium channel genes and 6 sodium channel genes, as well as a downregulation of 29 members of the solute carrier family.

406 We therefore conclude that B_2R antagonism not only impedes the viral entry process by
407 reducing ACE2, as we had hypothesized, but also counter-regulates cellular processes that
408 include GPCR signaling and transmembrane ion transport, which SARS-CoV-2 may utilize for
409 efficient replication and viral spread.
410
411 In conclusion, the results of this study suggest that B_2 receptor-antagonism protects airway
412 epithelial cells from SARS-CoV-2 spread by reducing ACE2 levels and by interfering with
413 several cellular signaling processes. Further research is needed to elucidate more details about
414 molecular mechanisms involved in the viral life cycle that kinin B_2 receptor antagonism targets
415 and underlie its effects against SARS-CoV-2 infection. Based on these data, we speculate that
416 the protective effects of B_2R antagonism could potentially prevent the early stages of COVID-
417 19 from progressing into severe acute respiratory distress syndrome (ARDS) with structural
418 airway damage and fibrotic changes. We therefore propose that the safe approved B_2R
419 antagonist icatibant be tested in clinical trials for two important aspects: 1) Treatment of early
420 COVID-19 disease targeting the replication and spread of the virus. 2) Optimized dosage
421 regimen to reflect pharmacokinetics and possible pharmacological tolerance at the receptor
422 level. Future controlled clinical trials must provide substantial evidence for optimal dosage
423 regimen, application, efficacy, and safety to investigate, whether KKS interference at the kinin
424 B_2 receptor level can prevent the escalation of COVID-19 to ARDS and long-term lung damage.
425

REFERENCES

1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615.
2. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy.* 2020;75(7):1730-1741.
3. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature.* 2021.
4. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med.* 2021.
5. Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *J Exp Med.* 2020;217(11).
6. Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). *Allergy.* 2020;75(10):2445-2476.
7. Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy.* 2021;76(2):428-455.
8. Bousquet J, Jutel M, Akdis CA, et al. ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). *Allergy.* 2021;76(3):689-697.
9. Du H, Dong X, Zhang JJ, et al. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. *Allergy.* 2021;76(2):510-532.
10. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell.* 2020;181(2):271-280 e278.
11. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. *J Virol.* 2010;84(24):12658-12664.
12. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature.* 2003;426(6965):450-454.
13. Diamond B. The renin-angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications. *J Exp Med.* 2020;217(8).
14. Schmaier AH. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. *J Thromb Haemost.* 2016;14(1):28-39.
15. Stukalov A, Girault V, Grass V, et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. *Nature.* 2021.
16. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature.* 2005;436(7047):112-116.
17. Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). *Physiol Rev.* 2018;98(1):505-553.
18. Meini S, Zanichelli A, Sbrojavacca R, et al. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key? *Front Immunol.* 2020;11:2014.
19. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem.* 2002;277(17):14838-14843.
20. van de Veerdonk FL, Netea MG, van Deuren M, et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. *Elife.* 2020;9.
21. Shen B, Harrison-Bernard LM, Fuller AJ, Vanderpool V, Saifudeen Z, El-Dahr SS. The Bradykinin B2 receptor gene is a target of angiotensin II type 1 receptor signaling. *J Am Soc Nephrol.* 2007;18(4):1140-1149.

22. Burch RM, Axelrod J. Dissociation of bradykinin-induced prostaglandin formation from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: evidence for G protein regulation of phospholipase A2. *Proc Natl Acad Sci U S A.* 1987;84(18):6374-6378.
23. Slivka SR, Insel PA. Phorbol ester and neomycin dissociate bradykinin receptor-mediated arachidonic acid release and polyphosphoinositide hydrolysis in Madin-Darby canine kidney cells. Evidence that bradykinin mediates noninterdependent activation of phospholipases A2 and C. *J Biol Chem.* 1988;263(29):14640-14647.
24. Yu HS, Lin TH, Tang CH. Involvement of intercellular adhesion molecule-1 up-regulation in bradykinin promotes cell motility in human prostate cancers. *Int J Mol Sci.* 2013;14(7):13329-13345.
25. Chen S, Zhang L, Xu R, et al. BDKRB2 +9/-9 bp polymorphisms influence BDKRB2 expression levels and NO production in knee osteoarthritis. *Exp Biol Med (Maywood).* 2017;242(4):422-428.
26. Souza PPC, Lundberg P, Lundgren I, Magalhaes FAC, Costa-Neto CM, Lerner UH. Activation of Toll-like receptor 2 induces B1 and B2 kinin receptors in human gingival fibroblasts and in mouse gingiva. *Sci Rep.* 2019;9(1):2973.
27. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. *Exp Physiol.* 2008;93(5):543-548.
28. Jia H. Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. *Shock.* 2016;46(3):239-248.
29. Lipcsey M, Persson B, Eriksson O, et al. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System. *Front Immunol.* 2021;12:627579.
30. Mansour E, Palma AC, Ulaf RG, et al. Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19. *Viruses.* 2021;13(2).
31. de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection. *Semin Thromb Hemost.* 2020;46(7):835-837.
32. Garvin MR, Alvarez C, Miller JI, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. *Elife.* 2020;9.
33. Kaplan AP, Ghebrehiwet B. Pathways for bradykinin formation and interrelationship with complement as a cause of edematous lung in COVID-19 patients. *J Allergy Clin Immunol.* 2021;147(2):507-509.
34. Roche JA, Roche R. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. *FASEB J.* 2020;34(6):7265-7269.
35. Bas M, Bier H, Greve J, Kojda G, Hoffmann TK. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. *Allergy.* 2006;61(12):1490-1492.
36. Eisenring M, vom Berg J, Kristiansen G, Saller E, Becher B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. *Nat Immunol.* 2010;11(11):1030-1038.
37. Sungnak W, Huang N, Becavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat Med.* 2020;26(5):681-687.
38. Yoshikawa T, Hill TE, Yoshikawa N, et al. Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection. *PLoS One.* 2010;5(1):e8729.
39. Leach JK, Spencer K, Mascelli M, McCauley TG. Pharmacokinetics of single and repeat doses of icatibant. *Clin Pharmacol Drug Dev.* 2015;4(2):105-111.

40. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506.
41. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-1062.
42. Burian E, Jungmann F, Kaissis GA, et al. Intensive Care Risk Estimation in COVID-19 Pneumonia Based on Clinical and Imaging Parameters: Experiences from the Munich Cohort. *J Clin Med.* 2020;9(5).
43. Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. *Cell Mol Immunol.* 2020.
44. Laing AG, Lorenc A, Del Molino Del Barrio I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. *Nat Med.* 2020;26(10):1623-1635.
45. Buszko M, Nita-Lazar A, Park JH, et al. Lessons learned: new insights on the role of cytokines in COVID-19. *Nat Immunol.* 2021;22(4):404-411.
46. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy.* 2020;75(7):1564-1581.
47. Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet.* 2021;397(10285):1637-1645.
48. Mostafa MM, Rider CF, Shah S, et al. Glucocorticoid-driven transcriptomes in human airway epithelial cells: commonalities, differences and functional insight from cell lines and primary cells. *BMC Med Genomics.* 2019;12(1):29.
49. Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. *Science.* 2014;343(6176):1221-1228.
50. Milewska A, Kindler E, Vkovski P, et al. APOBEC3-mediated restriction of RNA virus replication. *Sci Rep.* 2018;8(1):5960.
51. Wang Y, Schmitt K, Guo K, Santiago ML, Stephens EB. Role of the single deaminase domain APOBEC3A in virus restriction, retrotransposition, DNA damage and cancer. *J Gen Virol.* 2016;97(1):1-17.
52. Rodgers HC, Pang L, Holland E, Corbett L, Range S, Knox AJ. Bradykinin increases IL-8 generation in airway epithelial cells via COX-2-derived prostanoids. *Am J Physiol Lung Cell Mol Physiol.* 2002;283(3):L612-618.
53. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. *Nat Med.* 2018;24(6):739-748.
54. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol.* 2020.
55. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol.* 2020.
56. Mingfeng Liao YL, Jing Yuan, Yanling Wen, Gang Xu, Juanjuan Zhao, Lin Cheng, Jinxiu Li, Xin Wang, Fuxiang Wang, Lei Liu, Ido Amit, Shuye Zhang & Zheng Zhang. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. *Nat Med.* 2020.
57. Zmora P, Hoffmann M, Kollmus H, et al. TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1. *J Biol Chem.* 2018;293(36):13863-13873.
58. Kishimoto M, Uemura K, Sanaki T, et al. TMPRSS11D and TMPRSS13 Activate the SARS-CoV-2 Spike Protein. *Viruses.* 2021;13(3).

59. Han DP, Lohani M, Cho MW. Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. *J Virol.* 2007;81(21):12029-12039.
60. van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, et al. Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19. *JAMA Netw Open.* 2020;3(8):e2017708.
61. Abdel Hameid R, Cormet-Boyaka E, Kuebler WM, Uddin M, Berdiev BK. SARS-CoV-2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport. *Am J Physiol Lung Cell Mol Physiol.* 2021;320(3):L430-L435.
62. Stukalov A, Girault V, Grass V, et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. *Nature.* 2021;594(7862):246-252.

FIGURE LEGENDS

Figure 1. Induction of kallikreins and kinin receptor B_2 in the nasal mucosa of acutely positive Covid-19 patients

A) Volcano plot of significantly differentially regulated genes (DEGs = differentially expressed genes) in nasal brushings of patients that were acute positive for SARS-CoV-2 compared to healthy individuals (negative) using human miR microarray technology. Highlighted genes have a fold-change (FC)≥10 with P<0.05, genes in red are up-regulated, genes in blue are downregulated. B) Heat map of gene expression analysis of kallikrein genes and C) of genes of the kinin-kallikrein system (KKS) in nasal brushings comparing SARS-CoV-2 acute-positive patients to healthy controls. All entities with FC≥1.2 are shown. Asterisks indicate significantly regulated genes (P<0.05) in SARS-CoV-2-infected NHBEs compared to medium. Color code indicates Log2-fold change from low (blue) through 0 (white) to high (red). Duplicate gene names indicate the abundance of two or more isoforms of the same gene in the analysis. D) 3D-air-liquid interphase cultures from NHBEs were pre-treated for 24 hours with/without 1 nM B_2R antagonist from the basal side and subsequently infected with SARS-CoV-2 for 48 hours from the apical side.

E) Lactate dehydrogenase (LDH) cytotoxicity assay using the LDH Cytotoxicity Detection Kit PLUS studying the effect of increasing doses of the B_2R antagonist after 48 hours in primary NHBEs from 4 donors. Results are depicted as mean ± s.e.m. Statistical tests compared each dose of B_2R antagonist with 0 nM B_2R antagonist.

F) Cytotoxicity assay determining LDH release into the supernatants of cultures of SARS-CoV-2-infected NHBEs from 12 donors that were pre-treated for 24 hours with/without 1 nM B_2R antagonist.

G) Quantification of infectious particles in the supernatants of SARS-CoV-2-infected NHBEs from 10 donors that were pre-treated with/without 1 nM B_2R antagonist for 24 hours. Supernatants were titrated on Vero E6 cells and plaque assay was quantified 24 hours later.

Results are depicted as plaque forming units (PFU) per milliliter.

H) qPCR analysis of total SARS-CoV-2 RNA (viral genome and transcripts, which all contain the N1 sequence region) normalized to human *ACTB* of SARS-CoV-2-infected primary NHBE after 24 hours of pre-treatment with/without 1 nM B_2R antagonist followed by 24 hours of SARS-CoV-2 inoculation. For Figures 1E, F, and H, statistical tests compared SARS-CoV-2-infected versus uninfected samples or B_2R antagonist-treated versus untreated samples.

I) Analysis of human ACE2 gene expression using qPCR (n=10) and J) of human ACE2 protein levels analyzed by ELISA from cell lysates (n=6) after 24 hours of pre-treatment of NHBEs with/without 1 nM B_2R antagonist, followed by SARS-CoV-2 inoculation for 24 hours.

Figure 2. Treatment of NHBE with B_2R antagonist post-infection in repeated doses inhibits SARS-CoV-2 replication

A) *In vivo* mouse study. 12 sex-matched mice from three different strains per group were treated on day 0 with intranasal application of 1 µg murine IL-12Fc per mouse or PBS as control to mimic virus-induced airway inflammation. After 48h, mice were injected s.c. with 2 nmol of the B_2R antagonist icatibant per 10 g of body weight or PBS as control. The experiment was terminated either six hours or 24 hours later and murine lung ACE2 protein levels were analyzed by mouse ACE2 ELISA analysis. Circle: female; triangle: male. Black: C57BL/6, mid grey: C3H HeN, light grey: BALB/c strain. The experiment was carried out twice and the data in the figure represent the mean of each mouse type (strain / sex) of both experiments. Statistical tests compared B_2R antagonist -treated versus untreated groups.

B) Cytotoxicity assay determining LDH in supernatants from SARS-CoV-2-infected NHBEs from 12 donors that were treated with/without 1 nM B_2R antagonist after 6 hours of infection for another 24 hours. C) Quantification of infectious particles in the supernatants from SARS-CoV-2-infected NHBEs from 4 donors that were treated with/without 1 nM B_2R antagonist after 6 hours of infection for another 24 hours. Supernatants were titrated on Vero E6 cells and

plaque assay was quantified 24 hours later. Results are depicted as plaque forming units (PFU) per milliliter. For Figures 2B-C, statistical tests compared B_2R antagonist-treated versus untreated samples.

D) Relative quantification of total SARS-CoV-2 RNA (viral genome and transcripts, which all contain the N1 sequence region) and G) genomic SARS-CoV-2 RNA (containing the *RdRP* gene) normalized to housekeeping gene index of human *ACTB*, *HPRT*, *18S* in NHBEs from 8 independent donors that were infected with SARS-CoV-2 for 6 hours and then treated with increasing doses of the B_2R antagonist icatibant repeatedly every 24 hours for a total of 96 hours. In cells treated with E) 100 nM and F) 1000 nM icatibant for 48 hours and with H) 100 nM and I) 1000 nM icatibant for 72 hours, total SARS-CoV-2 RNA and genomic SARS-CoV-2 RNA were significantly reduced. Red indicates SARS-CoV-2 infection; blue indicates B_2R antagonist treatment. PRE indicates pre-treatment; POST indicates post-treatment. In Fig.2D-I, results are depicted as mean ± s.e.m. and statistical tests compared each dose of icatibant with 0 nM icatibant. Statistically significant differences were depicted as p-values *P<0.05, **P<0.01, and ***P<0.001. ns indicates non-significant. + infected / treated; - indicates not infected / not treated.

Figure 3. B_2R antagonism exhibits a protective and suppressive effect on gene expression profile of airway epithelial cells.

A) Volcano plots showing global gene expression changes induced by either treatment with B_2R antagonist or hydrocortisone (HC). Red indicates significantly upregulated entities; blue indicates significantly downregulated entities. Gene expression analysis of pre-treated NHBEs after 24 hours of SARS-CoV-2 infection. B) Heat map of gene expression analysis of genes involved in the epithelial antiviral response, analysis of the effects of SARS-CoV-2 infection. Only entities with significant changes between SARS-CoV-2 infection and medium are shown (gene expression fold change FC≥1.5 with P<0.05). C) Heat map of gene expression analysis

of genes involved in the acute phase response are depicted. All entities are shown. Asterisks indicate significantly regulated genes (P<0.05) in SARS-CoV-2 compared to medium. D) Heat map of gene expression analysis of known and potential virus entry receptors are depicted. All entities are shown. Color code indicates Log2-fold change from low (blue) through 0 (white) to high (red). Asterisks indicate significantly regulated genes (P<0.05) in SARS-CoV-2-infected NHBEs compared to medium. Duplicate gene names indicate the presence of two or more isoforms of the same gene in the analysis. E) Analysis of *TMPRSS2* gene expression by qPCR after 24 hours of pre-treatment with/without 10 µM hydrocortisone (HC) followed by 24 hours of SARS-CoV-2 inoculation. Red indicates SARS-CoV-2 infection; yellow indicates pre-treatment with hydrocortisone (HC). Statistical tests compared SARS-CoV-2-infected versus uninfected samples or B_2R antagonist-treated versus untreated samples.
F) Quantification of infectious particles in the supernatants of SARS-CoV-2-infected NHBEs from 10 donors that were pre-treated with/without 10 µM hydrocortisone (HC) for 24 hours. Supernatants were titrated on Vero E6 cells. The plaque assay was quantified 24 hours later. Results are depicted as plaque forming units (PFU) per milliliter.

Figure 4. B_2R antagonism exhibits a protective and suppressive effect on gene expression profile of airway epithelial cells.

GO term enrichment analysis, which results from the string network analysis of significant DEGs from the gene expression analysis comparing infected NHBE pretreated with B_2R antagonist with untreated infected NHBE (SARS-CoV-2 + B_2R antagonist *versus* SARS-CoV-2). Depicted are enrichment of A) GO-term GO:0007186 "G protein-coupled receptor signaling pathway" and B) GO-term GO:0006811 "Ion transport". Genes that were significantly upregulated in the comparison SARS-CoV-2 versus medium are highlighted in red. C) Venn diagram showing the cut set of upregulated membrane-bound cell surface receptors in SARS-CoV-2 *versus* medium and of downregulated DEGs in SARS-CoV-2 + icatibant *versus* SARS-

692 CoV-2 (FC≥1.5; P≤0.05). D) Heat map of gene expression analysis of the 35 membrane-bound
693 cell surface receptors defined in cut set from Fig.4C, all upregulated upon SARS-CoV-2
694 infection and downregulated upon pre-treatment with B_2R antagonist are depicted. Only entities
695 with significant changes between SARS-CoV-2 infection and medium (up) and between SARS-
696 CoV-2 + B_2R antagonist and SARS-CoV-2 (down) are shown (gene expression fold change
697 FC≥1.5 with P<0.05). Color code indicates Log2-fold change from low (blue) through 0 (white)
698 to high (red). Duplicate gene names indicate the abundance of two or more isoforms of the same
699 gene in the analysis.

700
701

Table 1. Demographic data of patient cohort

Parameter	Negative (n = 7)	Positive acute (n = 4)	p-value
Age (years)*	35.86 ± 3.86	37.50 ± 8.78	n.s.
Sex (m/f)	2/5	1/3	
IgM (ng/mL)	1.32 ± 0.28	4.34 ± 2.81	n.s.
IgG (ng/mL)	0.48 ± 0.08	67.08 ± 19.51	0.0061

negative: tested negative in SARS-CoV-2 qPCR; positive acute: tested positive in SARS-CoV-2 qPCR; IgM: immunoglobulin M; IgG: immunoglobulin G; values are depicted as mean ± s.e.m.; n.s. not significant
*at informed consent procedure and inclusion into study

FIGURE 1



FIGURE 2



Treatment post-infection:



FIGURE 3



FIGURE 4

membrane-bound cell surface receptor DEGs

SARS-CoV-2 + B_2R-ant vs SARS-CoV-2



C - Counter-regulation of SARS-CoV-2-induced DEGs by B_2R antagonist



upregulated DEGs
SARS-CoV-2
vs medium

downregulated DEGs
SARS-CoV-2 + B_2R-ant
vs SARS-CoV-2

D - Membrane-bound cell surface receptors